Lipid metabolism drives osimertinib resistance in non-small cell lung cancer

ABSTRACT: Untargeted lipidomics on pharmacologically-induced non-small cell lung cancer cell models of osimertinib resistance (PC9R5 and PC9R6) and osimertinib sensitive control (PC9P). Six replicates per condition.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Zoe Hall  

PROVIDER: MSV000099821 | MassIVE | Mon Nov 10 06:36:00 GMT 2025

REPOSITORIES: MassIVE